A story of targeted drug delivery formulation of Genistein and Chitosan combination opening doors to healing potential

Abstract

Naturally occurring compounds have attracted great attention for drug delivery purposes due to their safety, sustainability, and therapeutic versatility. In particular, an isoflavone with antioxidant and anticancer activity, called genistein, and a biodegradable polymer with superior carrier properties, known as chitosan, have both been proven promising for biomedical applications. However, the low solubility of genistein and the variable absorption profile of chitosan call for new formulation approaches. In this review, the current evidence on various genistein-chitosan combinations is compiled and discussed, considering their bioactive properties, delivery mechanisms, applications in disease management, clinical relevance, regulatory aspects, and future opportunities in targeted drug delivery. Literature indicates that chitosan-based encapsulation of genistein enhances the solubility, stability, and controlled release of the encapsulated genistein, resulting in improved therapeutic activities. Indications include oncology, osteoporosis, wound healing, or neuro, metabolic, and degenerative disorders. New developments in the field of nanotechnology, including liposomal system carriers, micelles, and prodrug methods, have also expanded the formulation possibilities. Regulatory frameworks in major markets prioritize safety, biocompatibility, and quality control, while sustainability and consumer acceptance are emerging as influential determinants of commercialization pathways. The combination of genistein and chitosan represents a paradigm shift in drug delivery, offering a more patient-friendly and environmentally friendly approach. Even with clean preclinical and early clinical data, implementation in routine practice requires strong human testing, standardized regulations, and scalable technologies for product manufacturing.

Keywords

• Genistein
• Chitosan
• Drug delivery systems
• Regulatory
• Bioactive compounds

References

1. Yeligar RR, Sarwa KK, Chandrakar M, Jangde MS. Nanotechnology-Based Delivery of Genistein to Overcome Physicochemical Hindrance and Enhance Therapeutic Response in Skin Cancer 2023; 13: 1339–58.
2. Coutinho AJ, Pinheiro M, Neves AR, Pinto MM. Therapeutic potential of genistein: preclinical studies, clinical evidence, and nanotechnology application 2023; 30: 2480–2517.
3. Xing Y, Shen W, Sun C, Wang R, Fan B, Liang G. Genistein-chitosan derivative nanoparticles for targeting and enhancing the anti-breast cancer effect of tamoxifen in vitro 2024.
4. Bansal K, Singh V, Mishra S, Bajpai M. Articulating the Pharmacological and Nanotechnological Aspects of Genistein: Current and Future Prospectives 2024; 25: 807–24.
5. Rasheed S, Rehman K, Shahid M, Suhail S, Akash MSH. Therapeutic potentials of genistein: New insights and perspectives 2022; 46.
6. Sharma N, Tiwary N, Behl T, Singh S, Gupta S, Anwer MdK, et al. Traversing the Vivid Pharmacological and Nanotechnological Facets of Genistein: Insights into the Past, Present and Future Trends 2023; 13: 1470–1500.
7. Al-Janabi AHA, Hayati Roodbari N, Homayouni Tabrizi M. Investigating the anticancer and anti-angiogenic effects of graphene oxide nanoparticles containing 6-gingerol modified with chitosan and folate 2023; 14: 69.
8. Rahman MH, Mondal MIH. Stability, challenges, and prospects of chitosan for the delivery of anticancer drugs and tissue regenerative growth factors 2024; 10.

9. Dessale M, Mengistu G, Mengist HM. Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis 2022; 17: 3735.
10. Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges 2021; 16: 173.
11. Nasir A, Khan A, Li J, Naeem M, Khalil AAK, Khan K, et al. Nanotechnology, A Tool for Diagnostics and Treatment of Cancer 2021; 21: 1360–76.
12. Shete V, Mahajan NM, Shivhare R, Akkewar A, Gupta A, Gurav S. Genistein: A promising phytoconstituent with reference to its bioactivities 2024; 38: 3935–53.
13. Naeem H, Momal U, Imran M, Shahbaz M, Hussain M, Alsagaby SA, et al. Anticancer perspectives of genistein: a comprehensive review 2023; 26: 3305–41.
14. Hou S. Genistein: Therapeutic and Preventive Effects, Mechanisms, and Clinical Application in Digestive Tract Tumor 2022; 2022: 1–10.
15. Rossi YE, Vanden Braber NL, Díaz Vergara LI, Montenegro MA. Bioactive Ingredients Obtained from Agro-industrial Byproducts: Recent Advances and Innovation in Micro- and Nanoencapsulation 2021; 69: 15066–75.
16. Sharma S, Gupta P, Kawish SM, Ahmad S, Iqbal Z, Vohora D, et al. Novel Chitosan-Coated Liposomes Coloaded with Exemestane and Genistein for an Effective Breast Cancer Therapy 2024; 9: 9735–52.
17. Yadav S, Singh A, Palei NN, Pathak P, Verma A, Yadav JP. Chitosan-Based Nanoformulations: Preclinical Investigations, Theranostic Advancements, and Clinical Trial Prospects for Targeting Diverse Pathologies 2024; 25: 263.
18. Javed Z, Khan K, Herrera-Bravo J, Naeem S, Iqbal MJ, Sadia H, et al. Genistein as a regulator of signaling pathways and microRNAs in different types of cancers 2021; 21: 388.
19. Komeil IA, Abdallah OY, El-Refaie WM. Surface modified genistein phytosome for breast cancer treatment: In-vitro appraisal, pharmacokinetics, and in-vivo antitumor efficacy 2022; 179: 106297.
20. Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA, et al. Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits 2021; 2021: 3268136.
21. Konstantinou EK, Gioxari A, Dimitriou M, Panoutsopoulos GI, Panagiotopoulos AA. Molecular Pathways of Genistein Activity in Breast Cancer Cells 2024; 25: 5556.
22. Wu Z, Liu L. The protective activity of genistein against bone and cartilage diseases 2022; 13: 1016981.
23. Gupta N, Gupta S, Kumar M, Guarve K, Dhanawat M, Sharma V. Therapeutic Potential of Genistein and its Derivatives as a Target for Anticancer Agents 2023; 8: e202204924.
24. Pradeep Prabhu P, Mohanty B, Lobo CL, Balusamy SR, Shetty A, Perumalsamy H, et al. Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery 2024; 22: 574.
25. Garbiec E, Cielecka-Piontek J, Kowalówka M, Hołubiec M, Zalewski P. Genistein—opportunities related to an interesting molecule of natural origin 2022; 27: 815.
26. Zivarpour P, Hallajzadeh J, Asemi Z, Sadoughi F, Sharifi M. Chitosan as possible inhibitory agents and delivery systems in leukemia 2021; 21: 544.
27. Li M, Liu Y, Weigmann B. Biodegradable polymeric nanoparticles loaded with flavonoids: A promising therapy for inflammatory bowel disease 2023; 24: 4454.
28. Kermawan P, Yasa I, Jawi IM, Suyasa IK, Karna MB. The pharmacological effects of glucosamine chondroitin, chitosan, and phytoestrogen on knee osteoarthritis 2024; 12: 1.
29. Cheng X, Li D, Cui R. Introducing a novel therapeutic supplement for osteoporosis: Remedial, cytotoxicity and antioxidant effects of plant extract green-formulated gold nanoparticles 2024; 12: 9–16.
30. Čoma M, Lachová V, Mitrengová P, Gál P. Molecular changes underlying genistein treatment of wound healing: a review 2021; 43: 127–41.
31. Jahan A, Akhtar J, Badruddeen, Jaiswal N, Ali A, Ahmad U. Recapitulate genistein for topical applications including nanotechnology delivery 2022; 52: 1306–17.
32. Prajapati SK, Jain D, Joshi S, Kesharwani P, Maji S. Dietary Polyphenols for the Management of Skin Diseases and Wound Healing. Dietary Polyphenols in Human Diseases.; CRC Press 2022; pp. 207–28.
33. Dholakia J, Prabhakar B, Shende P. Pulmonary administration of cross-linked chitosan nanoparticles of genistein for regulating blood glucose 2024; 276: 133854.
34. Gulati N, Dua K, Dureja H. Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases 2021; 185: 20–30.
35. Abbas H, Sayed NSE, Youssef NAHA, ME Gaafar P, Mousa MR, Fayez AM, et al. Novel luteolin-loaded chitosan decorated nanoparticles for brain-targeting delivery in a sporadic Alzheimer’s disease mouse model: Focus on antioxidant, anti-inflammatory, and amyloidogenic pathways 2022; 14: 1003.
36. Zameer S, Ali J, Vohora D, Najmi AK, Akhtar M. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer’s disease in intracerebroventricular streptozotocin model for brain delivery 2021; 29: 199–216.
37. Matías-Guiu J, Matías-Guiu JA, Montero-Escribano P, Barcia JA, Canales-Aguirre AA, Mateos-Diaz JC, et al. Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis 2020; 11: 638.
38. Bicker J, Fortuna A, Alves G, Falcão A. Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders 2020; 26: 594–619.
39. Jahan A, Akhtar J, Badruddeen, Jaiswal N, Ali A, Ahmad U. Recapitulate genistein for topical applications including nanotechnology delivery 2022; 52: 1306–17.
40. Muraleedharan A, Ray SK. Epigallocatechin-3-gallate and genistein for decreasing gut dysbiosis, inhibiting inflammasomes, and aiding autophagy in Alzheimer’s disease 2024; 14: 96.
41. Arora S, Bajaj T, Kumar J, Goyal M, Singh A, Singh C. Recent advances in delivery of peptide and protein therapeutics to the brain 2024; 388: 54–66.
42. Pradhan P, Jana K, Ghosh S, Debnath B, Rout SK, Rai VK, et al. Recent Advances in Bioactive Flavonoids-based Nanotherapeutics as Promising Neuroprotectants in Epilepsy 2025; 18.
43. Feiz MS, Meshkini A. Targeted delivery of adenosine 5′-triphosphate using chitosan-coated mesoporous hydroxyapatite: A theranostic pH-sensitive nanoplatform with enhanced anti-cancer effect 2019; 129: 1090–1102.
44. Shen C-L, Schuck A, Tompkins C, Dunn DM, Neugebauer V. Bioactive compounds for fibromyalgia-like symptoms: A narrative review and future perspectives 2022; 19: 4148.
45. De Gregori M, Muscoli C, Schatman M, Stallone T, Intelligente F, Rondanelli M, et al. Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach 2016; Volume 9: 1179–89.
46. Bostani RJ, Kohnehshahri MP, Tabatabaei ZG, Pouryaee A. Chitosan/Alginate-loaded Astragalus hamosus shows ameliorating effects on lipid profile, inflammatory and hormonal parameters, and reduces miRNA-222 expression in Polycystic Ovary Syndrome Rats 2024.
47. Sukrasno SW, RAIHANAH C. The Development of Microcapsules of Isoflavone Extract Fraction from Soya Tempeh as Supplement for Polycystic ovary Syndrome (PCOS) 2023: 1–13.
48. Liu S, Jia Y, Meng S, Luo Y, Yang Q, Pan Z. Mechanisms of and potential medications for oxidative stress in ovarian granulosa cells: a review 2023; 24: 9205.
49. Abdullah S, Md S, Altamimi AA, Alahdal H, Ali R, Alkreathy HM, et al. Preparation, optimization, and characterization of genistein-ginseng long-acting polymeric gel as a breast cancer treatment alternative 2024; 15: 257.
50. Castaño M, Martínez E, Osorio M, Castro C. Development of genistein drug delivery systems based on bacterial nanocellulose for potential colorectal cancer chemoprevention: effect of nanocellulose surface modification on genistein adsorption 2022; 27: 7201.
51. Jangid AK, Solanki R, Patel S, Pooja D, Kulhari H. Genistein encapsulated inulin-stearic acid bioconjugate nanoparticles: formulation development, characterization and anticancer activity 2022; 206: 213–21.
52. Razi MA. Chitosan Oligosaccharides as a Nanomaterial Platform: Biological Properties and Applications in the Biomedical and Pharmaceutical Fields 2022; 26: 2.
53. Chanphai P, Tajmir-Riahi HA. Folic acid-chitosan Nanomaterials for delivery of dietary polyphenols 2021; 2: 57–66.
54. Mahmudi H, Adili-Aghdam MA, Shahpouri M, Jaymand M, Amoozgar Z, Jahanban-Esfahlan R. Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease 2022; 12: 1054029.
55. Garbiec E, Rosiak N, Zalewski P, Tajber L, Cielecka-Piontek J. Genistein co-amorphous systems with amino acids: An investigation into enhanced solubility and biological activity 2023; 15: 2653.
56. Jaiswal KS, Malka O, Shauloff N, Bersudsky M, Voronov E, Gupta B, et al. Genistein carbon dots exhibit antioxidant and anti-inflammatory effects in vitro 2023; 223: 113173.
57. Kermawan P, Yasa I, Jawi IM, Suyasa IK, Karna MB. The pharmacological effects of glucosamine chondroitin, chitosan, and phytoestrogen on knee osteoarthritis 2024; 12: 1.
58. Naeem H, Momal U, Imran M, Shahbaz M, Hussain M, Alsagaby SA, et al. Anticancer perspectives of genistein: a comprehensive review 2023; 26: 3305–41.
59. Ozkan G, Ceyhan T, Çatalkaya G, Rajan L, Ullah H, Daglia M, et al. Encapsulated phenolic compounds: clinical efficacy of a novel delivery method 2024; 23: 781–819.
60. Patel N, Patel P. QbD-driven Formulation Development and Evaluation of Genistein Nanoparticles for Prostate Cancer 2025; 19: 53–71.
61. Liu C, Tang C, Yin C. Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy 2022; 283: 119097.
62. Home | ClinicalTrials.gov (homepage on the Internet). n.d. (cited 2025 Sept 19) Available from: (https://clinicaltrials.gov/).
63. Inbathamizh L, Nutraceuticals DP-… of, …, undefined 2022. Quality Assurance of Nutraceuticals and Their Approval, Registration, Marketing n.d.
64. Thakur S, Gupta MM, Fruits DS-N, for F, undefined 2024. Nutraceuticals regulation: an overview of the regulatory frameworks in USA, EU, and Japan n.d.
65. Umegaki K. Regulatory aspects of nutraceuticals: Japanese perspective. Nutraceuticals.; Elsevier 2021; pp. 1299– 1307.
66. Pradhan SS. Method Development and Stability Study to Determine Amount of Genistein Present in Formulation Intended for Use in Pediatric Asthma. Master’s Thesis. University of Colorado Denver, Anschutz Medical Campus, 2023.
67. Gulati K, Thokchom SK, Joshi JC, Nutraceuticals AR-, undefined 2021. Regulatory guidelines for nutraceuticals in India: An overview n.d.
68. Ruini C, Rigamonti L, Zanni A, Bertani G, Carnevale G, Ferrari E, et al. Life cycle assessment of chemical synthesis of genistein and its glucosyl derivatives to be employed in the modulation of angiogenesis of hepatocellular cancer 2023; 36: 101328.
69. Wang Z, Li X, Dai Y, Yin L, Azi F, Zhou J, et al. Sustainable production of genistin from glycerol by constructing and optimizing Escherichia coli 2022; 74: 206–19.
70. Wan S, Wei H, Quan R, Luo Z, Wang H, Liao B, et al. Soybean extract firstly used as a green corrosion inhibitor with high efficacy and yield for carbon steel in acidic medium 2022; 187: 115354.
71. Khang A, Akhai S. Green intelligent and sustainable manufacturing: key advancements, benefits, challenges, and applications for transforming industry 2024: 405–17.
72. Jadhav HB, Sablani S, Gogate P, Annapure U, Casanova F, Nayik GA, et al. Factors governing consumers buying behavior concerning nutraceutical product 2023; 11: 4988–5003.
73. Singh AK, Raj A, Ranjan J. Demographics and Cultural Influences on Nutraceutical Purchase Intentions A Quantitative Analysis of Consumer Behaviour in Urban India. 2024; 13.
74. Laderas ML. Key factors influencing nutraceutical purchase decisions 2024.
75. Hassan HA, Ali AI, ElDesawy EM, ElShafeey AH. Pharmacokinetic and pharmacodynamic evaluation of gemifloxacin chitosan nanoparticles as an antibacterial ocular dosage form 2022; 111: 1497–1508.
76. Imbeah EP. In Vitro And In Vivo Kinetic Characteristics Of Chitosan-Pectin-Based Matrix Of Levodopa And Carbidopa. PhD Thesis. University Of Ghana, 2021.
77. Gharat SA, Momin MM, Khan T. Pharmacokinetics and Pharmacodynamics of Nanocarriers and Novel Drug Delivery Systems. In: Gharat SA, Momin MM, Khan T, Eds. Pharmacokinetics and Pharmacodynamics of Novel Drug Delivery Systems: From Basic Concepts to Applications.; Singapore: Springer Nature Singapore 2024; pp. 179–274.
78. Azad AK, Dayoob M. Synthesis, Characterization, and Applications of Green Materials in Drug Delivery. Encyclopedia of Green Materials.; Springer 2024; pp. 1–10.
79. Laddha AP, Kulkarni YA. Pharmacokinetics, pharmacodynamics, toxicity, and formulations of daidzein: An important isoflavone 2023; 37: 2578–2604.
80. Najjar A, Lange D, Géniès C, Kuehnl J, Zifle A, Jacques C, et al. Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment 2024; 15: 1421650.
81. Kassem NM, Abdelmegid YA, El-Sayed MK, Sayed RS, Abdel-Aalla MH, Kassem HA. Nutrigenomics and microbiome shaping the future of personalized medicine: a review article 2023; 21: 134.
82. Kiani AK, Bonetti G, Donato K, Kaftalli J, Herbst KL, Stuppia L, et al. Polymorphisms, diet and nutrigenomics 2022; 63: E125.
83. Nasir A, Bullo MirMH, Ahmed Z, Imtiaz A, Yaqoob E, Safdar M, et al. Nutrigenomics: Epigenetics and cancer prevention: A comprehensive review 2020; 60: 1375–87.
84. Gacche RN. Functional Foods, Nutraceuticals and Dietary Supplements in Cancer Prevention. Dietary Research and Cancer.; Singapore: Springer Singapore 2021; pp. 121–30.
85. Potential for Functional Foods and Nutraceuticals Genistein - Google Scholar (homepage on the Internet). n.d. (cited 2025 Sept 19) Available from: (https://scholar.google.com/scholar? hl=en&as_sdt=0%2C5&as_ylo=2021&as_yhi=2024&q=Potential+for+Functional+Foods+and+Nutraceuticals+Ge nistein+&btnG=).
86. Padhi S, Singh A, Orsat V, Routray W. Flavonoids as Functional Foods and Nutraceuticals: Recent Advances. In: Bashir K, Jan K, Ahmad FJ, Eds. Functional Foods and Nutraceuticals: Chemistry, Health Benefits and the Way Forward.; Cham: Springer International Publishing 2024; pp. 173–98.
87. Dixit V, Joseph Kamal SW, Bajrang Chole P, Dayal D, Chaubey KK, Pal AK, et al. Functional Foods: Exploring the Health Benefits of Bioactive Compounds from Plant and Animal Sources 2023; 2023: 1–22.
88. Qureshi I, Habib M, Bashir K, Jan K, Jan S. Introduction to Functional Foods and Nutraceuticals. In: Bashir K, Jan K, Ahmad FJ, Eds. Functional Foods and Nutraceuticals: Chemistry, Health Benefits and the Way Forward.; Cham: Springer International Publishing 2024; pp. 1–15.
89. Mondal S, Soumya NPP, Mini S, Sivan SK. Bioactive compounds in functional food and their role as therapeutics 2021; 4: 24–39.
90. Halder T, Mehta P, Acharya N. Trends in the functional food market and nutraceutical product development. Nutraceuticals for aging and anti-aging.; CRC Press 2021; pp. 1–26.
91. Parihar N, Naraharisetti T, Patil P, Vathsan S, Deepak BP. Future Trends in the Formulation of Nutraceuticals. Formulations, Regulations, and Challenges of Nutraceuticals.; Apple Academic Press 2025; pp. 81–104.
92. Katanić Stanković JS, Mihailović N, Mihailović V. Genistein: Advances on Resources, Biosynthesis Pathway, Bioavailability, Bioactivity, and Pharmacology. In: Xiao J, Ed. Handbook of Dietary Flavonoids.; Cham: Springer International Publishing 2023; pp. 1–40.
93. Daman R, Miglani M. Genistein: A Multifaceted Flavonoid with Diverse Medicinal Applications 2024.
94. Zhang C, Zheng W, Hong J, Kafouros M. The role of government policies in explaining the internationalization of Chinese firms 2022; 141: 552–63.
95. Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020 2022; 5: e2225973–e2225973.
96. Smith V, Wesseler JH, Zilberman D. New plant breeding technologies: An assessment of the political economy of the regulatory environment and implications for sustainability 2021; 13: 3687.
97. Wei H, Yao H. Environmental regulation, roundabout production, and industrial structure transformation and upgrading: Evidence from China 2022; 14: 3810.
98. Chatterjee S, Dhole A, Krishnan AA, Banerjee K. Mycotoxin monitoring, regulation and analysis in India: a success story 2023; 12: 705.
99. Wang C-K. Legal Aspects of Functional Food and Dietary Supplements in Medicinal Foods Around the World. In: Bogueva D, Ed. Consumer Perceptions and Food.; Singapore: Springer Nature Singapore 2024; pp. 143–80.
100. Pejčić T, Zeković M, Bumbaširević U, Kalaba M, Vovk I, Bensa M, et al. The role of isoflavones in the prevention of breast cancer and prostate cancer 2023; 12: 368.
101. Bamankar S, Londhe VY. Nutraceuticals Interventions for Effective Management of Paget’s Disease. Nutraceuticals and Bone Health.; Apple Academic Press 2024; pp. 145–74.
102. Heininger K. Aging is selected for, adaptive, and programmed. 31. Is there a fountain of youth? n.d.
103. Kung S. Local and Systemic Effects of Flavonoid Intake with Submaximal Cycling Exercise: A Randomized Controlled Trial. PhD Thesis. Utah State University, 2021.
104. Yang L, Zhao M, Liu M, Zhang W, Zhi S, Qu L, et al. Effects of Genistein on Lipid Metabolism, Antioxidant Activity, and Immunity of Common Carp (Cyprinus carpio L.) Fed with High-Carbohydrate and High-Fat Diets 2023; 2023: 1–16.
105. Pierzynowska K, Podlacha M, Gaffke L, Rintz E, Wiśniewska K, Cyske Z, et al. Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation 2024; 20: 1159–82.
106. Tran-Guzman A, Moradian R, Cui H, Culty M. In vitro impact of genistein and mono (2-ethylhexyl) phthalate (MEHP) on the eicosanoid pathway in spermatogonial stem cells 2022; 107: 150–65.
107. Sadeghian R, Shahidi S, Komaki A, Habibi P, Ahmadiasl N, Yousefi H, et al. Synergism effect of swimming exercise and genistein on the inflammation, oxidative stress, and VEGF expression in the retina of diabetic-ovariectomized rats 2021; 284: 119931.
108. An P, Wan S, Luo Y, Luo J, Zhang X, Zhou S, et al. Micronutrient Supplementation to Reduce Cardiovascular Risk 2022; 80: 2269–85.
109. Tian M, Cheng J, Guo M. Stability, Digestion, and Cellular Transport of Soy Isoflavones Nanoparticles Stabilized by Polymerized Goat Milk Whey Protein 2024; 13: 567.
110. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions 2023; 9.
111. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies 2021; 5: 951–67. Khan MI, Hossain MI, Hossain MK, Rubel MHK, Hossain KM, Mahfuz AMUB, et al. Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review 2022; 5: 971–1012.
112. Puri V, Nagpal M, Singh I, Singh M, Dhingra GA, Huanbutta K, et al. A comprehensive review on nutraceuticals: therapy support and formulation challenges 2022; 14: 4637.
113. Rane BR, Amkar AJ, Patil VS, Vidhate PK, Patil AR. Opportunities and challenges in the development of functional foods and nutraceuticals 2024: 227–54.
114. Chopra AS, Lordan R, Horbańczuk OK, Atanasov AG, Chopra I, Horbańczuk JO, et al. The current use and evolving landscape of nutraceuticals 2022; 175.
115. Kumar M, Pandey SS, Kumar P, Yadav VK, Shukla AK. Nutraceuticals Manufacturing Challenges in Fast Growing Food Segment in India. Formulations, Regulations, and Challenges of Nutraceuticals.; Apple Academic Press 2025; pp. 255–84.